Product Description: Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies[1].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Tzu-Yuan Chao, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.
CAS Number: 2419087-87-7
Molecular Weight: N/A
Research Area: Infection
Solubility: 10 mM in DMSO
Target: RABV